Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
about
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial.A let-7 microRNA binding site polymorphism in the KRAS 3'UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population.MSDD: a manually curated database of experimentally supported associations among miRNAs, SNPs and human diseases.Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients.
P2860
Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR)
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Role of KRAS-LCS6 polymorphism ...... second line treatment (TAILOR)
@ast
Role of KRAS-LCS6 polymorphism ...... second line treatment (TAILOR)
@en
type
label
Role of KRAS-LCS6 polymorphism ...... second line treatment (TAILOR)
@ast
Role of KRAS-LCS6 polymorphism ...... second line treatment (TAILOR)
@en
prefLabel
Role of KRAS-LCS6 polymorphism ...... second line treatment (TAILOR)
@ast
Role of KRAS-LCS6 polymorphism ...... second line treatment (TAILOR)
@en
P2093
P2860
P50
P356
P1433
P1476
Role of KRAS-LCS6 polymorphism ...... second line treatment (TAILOR)
@en
P2093
Alessandro Bertolini
Anna Calcagno
Claudia Bareggi
Daniele Fagnani
Elena Copreni
Flavia Longo
Giuseppe Valmadre
Ida Pavese
Maria Agnese Fabbri
Maria Cristina Locatelli
P2860
P2888
P356
10.1038/SREP16331
P407
P577
2015-11-17T00:00:00Z